AbbVie Inc. logo

AbbVie Inc.

ABBV
HealthcareNYSEUnited States
204.18USD-0.75 (-0.37%)

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.

Therapeutic Areas & Key Products:

  • Immunology:
    HUMIRA (injection for autoimmune diseases), SKYRIZI (plaque psoriasis), RINVOQ (JAK inhibitor for rheumatoid arthritis)

  • Oncology:
    IMBRUVICA (CLL, SLL), VENCLEXTA (BCL-2 inhibitor for CLL/SLL)

  • Virology:
    MAVYRET (chronic HCV genotype 1–6 infection)

  • Gastroenterology & Endocrinology:
    CREON (pancreatic enzyme for exocrine pancreatic insufficiency),
    Synthroid (hypothyroidism),
    Linzess/Constella (IBS-C and chronic idiopathic constipation)

  • Urology & Hormonal Disorders:
    Lupron (prostate cancer, endometriosis, precocious puberty, uterine fibroid-related anemia)

  • Neurology:
    Duopa/Duodopa (levodopa-carbidopa gel for Parkinson’s disease),
    Ubrelvy (migraine)

  • Women’s Health:
    ORILISSA (endometriosis pain)

  • Eye Care:
    Lumigan/Ganfort (glaucoma),
    Alphagan/Combigan (glaucoma),
    Restasis (dry eye disease)

Other Notable Therapies: Botox Therapeutic (for chronic migraine, muscle spasms, and other neurological conditions)

AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc.

The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie's Business Strategy

AbbVie operates as a research-based biopharmaceutical company distinguished by its deep expertise in immunology, oncology, neuroscience, and virology. The company's business model centers on developing and commercializing innovative therapies that address serious diseases with significant unmet medical needs. AbbVie's portfolio includes both blockbuster drugs and…

Available on Finplify

Free account required

Sign up free

Our Take on AbbVie

Pros:

Diversified Biopharma Portfolio: AbbVie is a leading global biopharmaceutical company with strengths in immunology, oncology, neuroscience, and aesthetics. Its wide therapeutic focus provides multiple revenue drivers beyond a single product or segment.

Post-Humira Transition Underway: While Humira was AbbVie's longtime revenue cornerstone, the…

Available on Finplify

Free account required

Sign up free

Company Details

Exchange
NYSE
Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert A. Michael
Employees
55,000
IPO Date
2013-01-02
ISIN
US00287Y1091
Website
abbvie.com

Key Metrics

Market Cap
361.02BUSD
P/E Ratio (TTM)
86.34
Net Profit Margin
6.91%
Debt / Asset Ratio
0.51
Dividend Yield (TTM)
3.25%
Volume
563,630
Avg Volume
6.41M
Shares Outstanding
1.77B
Free Float
99.91%
β Beta
0.33
52W Range
164.4 - 244.8

Fundamental Analysis

Proprietary 5-category scoring system

Score Fingerprint

Section Scores

Profitability
3.1/5Average
Liquidity
2.0/5Weak
Leverage
1.5/5Poor
Cash Flow
4.0/5Good
Valuation
1.4/5Poor

Full Breakdown & Peer Ranking

See the detailed score for every metric and how this stock ranks against its sector peers

Unlock for free
Free to join

Unlock the full research on AbbVie

Get the full fundamental score breakdown, business strategy, our investment take, live charts and AI-powered briefings. All in one ad-free workspace.

300+ Curated Stocks

A hand-picked universe of world-class businesses across every major market and sector.

AI Analyst Briefings

Deploy your own AI analyst that monitors your portfolio and delivers daily intelligence reports.

Proprietary Fundamentals

Five-category scoring for every stock — profitability, liquidity, leverage, cash flow, and valuation.